GO
Loading...

Enter multiple symbols separated by commas

Perrigo Co

More

  • *Alexion offers $225.92 per Synageva share in cash and stock. May 6- Alexion Pharmaceuticals Inc on Wednesday said it agreed to buy Synageva BioPharma Corp for $8.4 billion, more than twice its market value, to expand its offering of potentially high-priced medicines for rare diseases. The medicine, which can cost more than $500,000 per year, generated sales of...

  • INTERVIEW-New-look GSK bets on consumer health spending Wednesday, 6 May 2015 | 7:19 AM ET

    LONDON, May 6- Consumers from New York to New Delhi are digging deeper in their pockets for over-the-counter remedies and health products, a trend GlaxoSmithKline is banking on to help shape the next chapter in its evolution. In the biggest shake-up in its 15- year history, GSK has just sold its cancer drugs to Novartis, while buying the Swiss group's vaccine...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co and believes it can complete the deal by year end. Mylan, on a conference call with analysts, said it is legally committed to take its offer directly to Perrigo shareholders under Irish takeover...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, said on Tuesday it is fully committed to acquiring Ireland- based Perrigo Co.. "We remain steadfast in our legally binding commitment to acquire Perrigo and have taken numerous concrete steps to lay out a clear and certain path towards completion," Mylan Chief Executive...

  • May 5- Generic drugmaker Mylan NV, at the center of a high-stakes, three-way takeover battle, on Tuesday reported slightly higher-than-expected first-quarter profit and said it was "steadfast" in its commitment to acquire Ireland- based Perrigo Co.. Perrigo last week rejected a sweetened $34 billion offer from Mylan. At the same time, Mylan is attempting to fend...

  • NEW YORK— Generic drugmaker Mylan raised its offer for over-the-counter medicines maker Perrigo Wednesday, but the Irish company again rejected Mylan's overture. Mylan said Wednesday it will pay $232.23 for each share of Perrigo in a mix of cash and stock, valuing Perrigo at about $34.1 billion. Perrigo, which is based in Dublin with U.S. headquarters in Allegan,...

  • NEW YORK, April 28- A federal judge dismissed claims by former Elan Corp and Wyeth shareholders accusing billionaire investor Steven A. Cohen's SAC Capital Advisors LP of violating federal racketeering law by conducting insider trading in the drugmakers' stocks. District Judge Victor Marrero in Manhattan said the civil claims brought under the Racketeer...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's $40 billion takeover offer on Monday, saying in a scathing letter that it grossly undervalued the company and that Mylan has no interest in payment in what it termed "high-risk" Teva stock. Mylan shares fell 5.7 percent to $71.71 on Nasdaq, and Teva fell 3.8 percent to $61.93 on the New York Stock...

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, saying it was too low and calling Teva stock an "unacceptable" currency. Mylan, which is pursuing its own takeover of Perrigo Co Plc, had been expected to reject the offer after having indicated that such a combination would not be a good fit.

  • April 27- Mylan NV rejected Teva Pharmaceutical Industries Ltd's unsolicited $40 billion takeover offer on Monday, but left the door open for talks. Mylan also said it remained committed to its offer for Perrigo Co Plc. Last week, Mylan said it would take its $31 billion offer for Perrigo directly to shareholders, in what is set to be one of the most high-profile...

  • Mylan rejects Teva's $40.1 billion buyout offer Monday, 27 Apr 2015 | 9:58 AM ET

    NEW YORK— Mylan N.V. rejected Teva Pharmaceuticals' $40.1 billion buyout offer, saying the cash-and-stock proposal undervalues the company. Mylan is trying to buy Perrigo Co. of Ireland for about $30 billion in cash and stock, combining its own generic drug business with Perrigo's position in over-the-counter medications and other nonprescription...

  • NEW YORK, April 24- Teva Pharmaceutical Industries' bid for Mylan NV would create a company controlling nearly 25 percent of the U.S. generics market, including drugs in short supply, according to industry experts and a Reuters review of regulatory filings. It is also pursuing a hostile takeover of drugmaker Perrigo Co Plc. Teva has already looked at the...

  • NEW YORK— Generic drugmaker Mylan is making official its offer for over-the-counter medicines maker Perrigo as it remains at the center of a three-way battle: Mylan wants to buy Perrigo, while a larger rival wants to buy Mylan. Perrigo has already rejected Mylan's offer and reiterated Friday it feels the bid, worth more than $30 billion, is too low.

  • April 22- Generic drugmaker Teva Pharmaceutical Industries Ltd said it could "promptly" divest some operations to obtain regulatory clearance for its proposed $40 billion takeover of smaller rival Mylan NV. Mylan, which has said a merger with Teva would be bad fit, plans to make a new offer for Perrigo Co Plc in the near term, CNBC reported on Wednesday.

  • April 22- Teva Pharmaceutical Industries Ltd said on Wednesday it could "promptly" divest some operations if necessary to obtain regulatory clearance for its proposed takeover of smaller rival Mylan NV. Meanwhile, Canonsburg, Pennsylvania- based Mylan is pursuing its own $29 billion unsolicited bid for Perrigo Co Plc, which the maker of over-the-counter...

  • April 21- Some of the top investors at Mylan NV, including Paulson& Co, are encouraging its board of directors to consider a takeover proposal from rival Teva Pharmaceutical Industries Inc, according to people familiar with the matter. Teva unveiled an unsolicited $40 billion takeover proposal on Tuesday for the Canonsburg, Pennsylvania- based company.

  • Perrigo rejects $205/share bid from Mylan Tuesday, 21 Apr 2015 | 4:26 PM ET

    April 21- Dublin- based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company. Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros acquisition of Omega Pharma and new products that are expected to generate about $1...

  • April 21- Perrigo Company PLC is set to reject a $29 billion unsolicited takeover offer from generics drugmaker Mylan NV as soon as this week, according to a source familiar with the matter. Teva said that its offer for Mylan is contingent on the company not completing an acquisition of Perrigo or any alternative transaction. Representatives from Perrigo and...

  • TEL AVIV/ NEW YORK, April 21- Generic drugmaker Teva Pharmaceutical Industries Ltd. on Tuesday proposed buying smaller rival Mylan for $40 billion, saying it was a better deal than Mylan's alternate offer to buy Perrigo Co. Teva said the stock-and-cash offer of $82 a share represented a 48 percent premium to Mylan's stock price on March 10, which it said was the...

  • Mylan last week announced a $29 billion offer to buy Perrigo Co Plc in a move that some analysts suggested was a tactic to help fend off an acquisition by larger rival Teva. Mylan Executive Chairman and former Chief Executive Officer Robert Coury said the Perrigo plans remain on track. "Mylan is fully committed to its stand-alone strategy, including its proposal...